Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

Summary

This phase II study is aim to investigate the efficacy, resistance mechanism, safety profile of first-line lorlatinib in China advanced ALK+ non-small cell lung cancer (NSCLC). Participants will receive continuous daily PO dosing of lorlatinib 100mg QD.

Timeline

Start

2023-08-18

Primary completion

2025-08-01

Completion

2030-08-01

Publications

• Lin JX, Zhou Q, Yan HH, Liu AW, Wu GW, Chu Q, Du YY, Cui JW, Cheng Y, Yang Y, Xu HP, Tu HY, Wu YL, Liu SM. A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203). Clin Lung Cancer. 2025 Sep;26(6):515-519. doi: 10.1016/j.cllc.2025.05.014. Epub 2025 May 28.

Drugs

Indications